New omicron subvariant largely evades neutralizing antibodies

A study at Karolinska Institutet shows that the coronavirus variant BA.2.75.2, an omicron sublineage, largely evades neutralizing antibodies in the blood and is resistant to several monoclonal antibody antiviral treatments. The findings, published in the journal The Lancet Infectious Diseases, suggest a risk of increased SARS-CoV-2 infections this winter, unless the new updated bivalent vaccines help to boost immunity in the population.